Info

Momenta Pharmaceuticals, Inc. (Momenta) is a biotechnology company with a product pipeline of mixture generic drugs. Momenta characterizes the structure and structure-process of mixture drugs to develop generic versions of marketed products. The Company's most advanced product candidate in its complex mixture generics drugs pipeline is M-Enoxaparin, which is designed to be a technology-enabled generic version of Lovenox (enoxaparin sodium injection), a low molecular weight heparin (LMWH) used to prevent and treat deep vein thrombosis (DVT) and to support the treatment of acute coronary syndromes (ACS). In its drugs pipeline, Momenta's lead candidate M118, is a LMWH designed to support the treatment of ACS. Momenta's other drug candidates include M356, a technology-enabled generic version of Copaxone (glatiramer acetate injection), and MI78 and M249, which are glycoproteins being developed as generic or follow-on versions of marketed therapeutic proteins.(Source: 10-K)